Literature DB >> 9252371

The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor.

S M Leal1, Q Liu, S S Huang, J S Huang.   

Abstract

Insulin-like growth factor-binding protein 3 (IGFBP-3) has been shown to inhibit cell growth by IGF-dependent and -independent mechanisms. The putative cell-surface IGFBP-3 receptor that mediates the IGF-independent growth inhibition has not been identified. Here we show that recombinant human IGFBP-3 inhibits 125I-transforming growth factor (TGF)-beta1 binding to the type V TGF-beta receptor (Mr 400,000) in mink lung epithelial cells. We also demonstrate that the approximately 400-kDa 125I-IGFBP-3 affinity-labeled putative IGFBP-3 receptor is immunoprecipitated by specific antiserum to the type V TGF-beta receptor. The 125I-IGFBP-3 affinity labeling of the putative receptor and IGFBP-3-induced growth inhibition as measured by DNA synthesis in these cells is blocked by a TGF-beta1 peptide antagonist. The 125I-IGFBP-3 affinity-labeled putative receptor can only be detected in cells expressing the type V TGF-beta receptor, but not in cells lacking the type V TGF-beta receptor. These results indicate that the type V TGF-beta receptor is the putative IGFBP-3 receptor and that IGFBP-3 is a functional ligand for the type V TGF-beta receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252371     DOI: 10.1074/jbc.272.33.20572

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Insulin-like growth factor binding proteins: IGF-dependent and -independent effects in the mammary gland.

Authors:  D J Flint; E Tonner; G J Allan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 2.  Insulin-like growth factor binding proteins (IGFBPs) in breast cancer.

Authors:  C M Perks; J M Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 3.  Cellular actions of insulin-like growth factor binding proteins.

Authors:  R J Ferry; L E Katz; A Grimberg; P Cohen; S A Weinzimer
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

4.  Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.

Authors:  B Mannhardt; S A Weinzimer; M Wagner; M Fiedler; P Cohen; P Jansen-Dürr; W Zwerschke
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 5.  Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology.

Authors:  Lynn C Shaw; Maria B Grant
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 6.  The role of insulin-like growth factor binding proteins in development.

Authors:  J M Pell; D A M Salih; L J Cobb; G Tripathi; A Drozd
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

Review 7.  Role of insulin-like growth factor binding proteins in mammary gland development.

Authors:  D J Flint; E Tonner; J Beattie; G J Allan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-08       Impact factor: 2.673

8.  IGFBP-3 sensitizes prostate cancer cells to interferon-gamma-induced apoptosis.

Authors:  Peng Fang; Vivian Hwa; Brian M Little; Ron G Rosenfeld
Journal:  Growth Horm IGF Res       Date:  2007-08-24       Impact factor: 2.372

9.  Role of insulin-like growth factor binding proteins (IGFBPs) in breast cancer proliferation and metastasis.

Authors:  Erin D Giles; Gurmit Singh
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.